Tanriover, M. D. Et Al. 2022. Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial. Vaccines , vol.10, no.11 .

Tanriover, M. D., Aydin, O. A., Guner, R., YILDIZ, O., Celik, I., Doganay, H. L., ... KÖSE, Ş.(2022). Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial. Vaccines , vol.10, no.11.

Tanriover, Mine Et Al. "Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial," Vaccines , vol.10, no.11, 2022

Tanriover, Mine D. Et Al. "Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial." Vaccines , vol.10, no.11, 2022

Tanriover, M. D. Et Al. (2022) . "Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial." Vaccines , vol.10, no.11.

@article{article, author={Mine Durusu Tanriover Et Al. }, title={Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial}, journal={Vaccines}, year=2022}